37 results
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
9 Nov 23
Condensed Consolidated Financial Statements
4:30pm
strategy is targeted at obtaining topline data readouts from two advanced-stage clinical indications by mid-2025 – (a) a randomized, controlled Phase
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
13 Sep 23
Notice of Annual General Meeting of Shareholders
4:42pm
. Singer is currently a corporate strategy consultant to biotech companies through his firm, Fika Bio Consulting LLC. Prior to that, Mr. Singer
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
inflammation, and an indication with a substantial unmet medical need that potentially represents a multibillion commercial market.
The revised strategy … revised strategy is targeted at obtaining topline data readouts from two advanced-stage clinical indications by mid-2025 – (a) a randomized
6-K
ENLV
Enlivex Therapeutics Ltd
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
a Phase III registrational trial upon its completion.
The Company’s revised strategy is targeted at obtaining topline data readouts from two advanced-stage
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
17 Apr 23
Enlivex Appoints Andrew Singer to its Board of Directors
8:03am
finance, mergers and acquisitions, and business strategy
Former EVP and CFO of Epizyme and Senior Biotech Investment Banker at Credit Suisse, Wells … , corporate finance, mergers and acquisitions, and business strategy from his extensive investment banking and executive management career
6-K
EX-99.1
l8fy57wighalf2i ds9h
31 Mar 23
Report of Foreign Private Issuer
4:30pm
6-K
EX-99.2
a8hhg054
2 Dec 22
Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.1
8pl4i
29 Aug 22
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells
8:01am
6-K
EX-99.2
pk7pz8ekr2r
22 Aug 22
Condensed Consolidated Financial Statements
8:08am
6-K
EX-99.2
hskexxosxd631l1vsqch
27 May 22
Condensed Consolidated Financial Statements
4:39pm
6-K
EX-99.1
k2562oz
23 May 22
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
8:03am
6-K
EX-99.1
1mpi48x7dzkwzuf
8 Mar 22
Enlivex Announces Issuance of Israeli Patent Covering Allocetra Derived from Pooled Donor Cells
8:03am
6-K
EX-99.1
ekgnrh4
13 Dec 21
Enlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Greece
8:00am
6-K
EX-99.1
u83fmz2
7 Dec 21
Enlivex Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece
8:01am
6-K
EX-99.1
6qd a3vycjz4wuc
22 Nov 21
Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update
8:00am
6-K
EX-99.1
jydn1k7nm0ro 6g
10 Nov 21
Spanish Regulator Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain
8:00am